ILpress February 2016

WuXi Collaboration with Israeli Partners

The Future of Cancer Therapy: An Interview with Yinon Ben-Neriah, Hebrew University

WuXi News

Dr. Ge Li Receives Executive of the Year Award from SCRIP

Over 1,100 Executives Signed-up for 4th Annual WuXi Global Forum at J.P. Morgan Conference

WuXi Healthcare Ventures Joins Financing Rounds for Twist Bioscience and Syros Pharmaceuticals

WuXi Plans $120 Million Investment in New Integrated Biologics Solution Center to Expedite Biologics Development from Ideas to Clinic

WuXi and MedImmune Form a Strategic Alliance to Develop Innovative Biologics in China for AstraZeneca

WuXi Healthcare Ventures II Closes with Oversubscription

WuXi Congratulates MSD on Receiving FDA Approval of ZEPATIER™

Congratulations to Chia Tai Tianqing Pharmaceutical Group and Janssen for Licensing Agreement

Combining Service and Investment: An Interview with Wei Li, Co-Founder of WuXi Healthcare Ventures

Developing a Novel ADC for Global Market via Innovative Three-party Collaboration – An Interview with Dr. Jiawen Han, Vice President, WuXi Biologics

Meet IDSU Leadership: An Interview with Tao Guo, VP of Medicinal Chemistry
In This Issue
Industry Beats

TAU links growth factor to development of Alzheimer’s disease (Source: Tel Aviv University)BioLight Reports Positive Second Clinical Study Results for its TeaRx Multi-Assay Test for Dry Eye Syndrome (Source: PR Newswire)Israeli Pharma Firm to Develop Alternative to Viagra (Source: The Times of Israel)Israeli Researchers Develop Novel Method To Treat Aggressive Blood Cancers (Source: No Camels)Breakthrough Israeli Research Improves HIV/AIDS Treatment, Could Lead To Cure (Source: No Camels)CollPlant Reports Positive Interim Trial Results for Vergenix, Indicated for the Treatment of Tendinopathy (Source: CollPlant)Can-Fite Announces 2016 Clinical Milestones for its Pipeline of Drugs in Six Indications (Source: Can-Fite)Compugen Achieves Third Preclinical Milestone in Cancer Immunotherapy Collaboration with Bayer (Source: Compugen)

Kamada’s Human Rabies Immune Globulin Successfully Meets Primary Endpoint in U.S. Pivotal Phase 2/3 Clinical Trial as a Post-Exposure Treatment (Source: Kamada)

Teva Announces Launch of Generic Ortho Tri-Cyclen® Lo in the United States (Source: Teva Pharmaceuticals)

Kite Pharma Expands Its Clinical and Research Partnership With the National Cancer Institute (NCI) for Next-Generation CAR Programs to Treat B-Cell Malignancies (Source: Kite Pharma)

BioLineRx Announces Collaboration with MSD to investigate the combination of KEYTRUDA (pembrolizumab) and BL-8040 in Pancreatic Cancer (Source: BioLineRx)

Sanara Ventures Cements Teva-Philips Ties (Source: Sanara Ventures)

J&J Backs Israeli Startup in $28M Round for Heart Failure Implant (Source: Fierce Medical Device)

Phillip Morris Invests $20m in Syqe Cannabis Inhaler (Source: iCAN)

Takeda Provides Further Information about its New Business Venture with Teva (Source: Takeda)

Adicet Bio Announces Closing of $51 Million Series A Financing and Acquisition of Applied Immune Technologies (Source: PR Newswire)

CartiHeal Raises $15 Million (Source: PR Newswire)

Insightec Secures $22 Million and Appoints Maurice R. Ferre, MD, as CEO (Source: Insightec)

Israeli Catheter Co Pi-Cardia Raises $10m (Source: Globes)

KAHR Medical Reports Raising $12M At First Closing Of Its Series B Private Equity Financing (Source: KAHR Medical)

Drug Approvals & Designations

Upcoming Events

February 22-23, 2016
Tel Aviv University, Tel Aviv
March 9, 2016
Independence Park, Tel Aviv
March 29, 2016
The Hebrew University of Jerusalem, Jerusalem
Follow us on TwitterView our profile on LinkedIn